Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05113537
What this trial is testing

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+4 more
Vadim S Koshkin 30
Testing effectiveness (Phase 2)WithdrawnNCT07025512
What this trial is testing

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Who this might be right for
Metastatic Castration Resistant Prostate CancerCytopeniaAnemia+1 more
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT07365995
What this trial is testing

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
BioNTech SE 736
Testing effectiveness (Phase 2)UnknownNCT04603833
What this trial is testing

SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Who this might be right for
Prostate Cancer Metastatic
Jiangsu HengRui Medicine Co., Ltd. 150
Not applicableLooking for participantsNCT07093801
What this trial is testing

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals 300
Testing effectiveness (Phase 2)Ended earlyNCT02933801
What this trial is testing

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Who this might be right for
Prostate Cancer MetastaticProstate Cancer
Swiss Cancer Institute 92
Early research (Phase 1)Looking for participantsNCT05283330
What this trial is testing

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Who this might be right for
Cervical CancerBreast CancerColon Cancer+4 more
Orano Med Theranostics, SAS 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT04015622
What this trial is testing

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
British Columbia Cancer Agency 100
Testing effectiveness (Phase 2)Study completedNCT01718353
What this trial is testing

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Sanofi 63
Testing effectiveness (Phase 2)UnknownNCT05579184
What this trial is testing

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2

Who this might be right for
Metastatic Castration-resistant Prostate Cancer, mCRPC
FutureChem 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT07047118
What this trial is testing

JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals 138
Early research (Phase 1)Looking for participantsNCT07103018
What this trial is testing

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Who this might be right for
Metastatic Castration-resistant Prostate CancerMetastatic Castration-Resistant Prostate Cancer PatientsMetastatic Castration-resistant Prostate Cancer, mCRPC+2 more
K36 Therapeutics, Inc. 144
Early research (Phase 1)Study completedNCT04179396
What this trial is testing

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT06383052
What this trial is testing

177Lu-NYM032 Injection in mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Norroy Bioscience Co., LTD 30
Post-approval studies (Phase 4)UnknownNCT03432949
What this trial is testing

Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

Who this might be right for
Metastatic Prostate Cancer
University Health Network, Toronto 24
Testing effectiveness (Phase 2)Ended earlyNCT05489991
What this trial is testing

TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Tceleron Therapeutics, Inc. 1
Not applicableStudy completedNCT03896984
What this trial is testing

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer 346
Testing effectiveness (Phase 2)Study completedNCT02463799
What this trial is testing

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Testing effectiveness (Phase 2)WithdrawnNCT02035124
What this trial is testing

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Who this might be right for
Advanced Prostate Cancer
SCRI Development Innovations, LLC
Early research (Phase 1)WithdrawnNCT03110588
What this trial is testing

Phase I Trial of PACE for Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
University of Alabama at Birmingham
Next Page